Fosamax and Osteonecrosis of the Jaw: Scientific Evidence of Causation

Latest update (2026-05)

FDA enforcement record (Ongoing): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. [source]

From General Health Education to Targeted Pharmaceutical Risk Assessment

The legacy context of general health and science information has long served as a foundation for public understanding of medical conditions and pharmaceutical effects. Within this broad framework, discussions of bone health, metabolic disorders, and therapeutic interventions have provided essential background for both clinicians and patients. This heritage emphasizes the importance of informed decision-making and awareness of potential risks associated with medical treatments. Transitioning from this general health perspective, a more focused examination emerges regarding specific pharmaceutical exposures and their potential consequences. The domain of mass production introduces considerations of how widely prescribed medications may be associated with adverse outcomes in certain populations. In particular, the relationship between bisphosphonate therapy and skeletal complications has drawn attention from both medical researchers and occupational health specialists. This pivot toward occupational exposure concern does not require detailed mechanistic explanations but rather acknowledges that patterns of medication use and patient characteristics can influence risk profiles. The shift from broad health education to targeted inquiry about specific drug-exposure scenarios represents a natural progression in scientific discourse. By maintaining a neutral academic tone, this transition respects the complexity of pharmaceutical risk assessment while avoiding premature conclusions about causation. The focus remains on how general health principles can inform more specialized investigations into medication-related outcomes.

Bridging General Health Principles to Fosamax and ONJ

Building on the foundation of general health education, we now turn to a specific pharmaceutical agent and its documented adverse effects. Fosamax (alendronate sodium) is a bisphosphonate medication approved for the treatment and prevention of osteoporosis in postmenopausal women, treatment to increase bone mass in men with osteoporosis, treatment of glucocorticoid-induced osteoporosis, and treatment of Paget's disease of bone (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Its mechanism involves inhibiting bone resorption, which reduces fracture risk but also alters normal bone remodeling. A recognized adverse effect associated with bisphosphonate use, including Fosamax, is osteonecrosis of the jaw (ONJ), a condition characterized by exposed, non-healing bone in the maxillofacial region. The clinical presentation of ONJ typically involves exposed bone in the jaw that persists for more than eight weeks, often accompanied by pain, swelling, infection, or delayed healing after dental procedures. The condition can occur spontaneously but is generally associated with tooth extraction and/or local infection with delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Diagnosis relies on clinical examination and imaging, with exclusion of metastatic disease or other causes of jaw necrosis.

Mechanistic Pathways and Risk Factors for ONJ

The multiscale characterization of jawbone provides comprehensive information that can help better understand jawbone-specific responses to bone-related complications, including bisphosphonate-related osteonecrosis of the jaw (https://pubmed.ncbi.nlm.nih.gov/40345077/). This research highlights the unique structural and mechanical properties of the jawbone that may predispose it to complications from bisphosphonate therapy. Mechanistic pathways linking Fosamax to ONJ involve the drug's potent inhibition of osteoclast activity. Bisphosphonates like alendronate accumulate in bone, particularly at sites of high turnover such as the jaw, and suppress bone remodeling. This suppression can impair the ability of the jawbone to repair microdamage, especially after dental trauma or infection. The resulting avascular necrosis is thought to arise from a combination of reduced bone turnover, compromised blood supply, and local infection. Known risk factors for ONJ include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (e.g., periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection, ill-fitting dentures) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The risk of ONJ may increase with duration of exposure to bisphosphonates (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

Adequacy of Warnings and Causation Evidence

Regarding the adequacy of warnings, the prescribing information for Fosamax includes a specific section on osteonecrosis of the jaw. The label states that ONJ has been reported in patients taking bisphosphonates, including Fosamax (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). It also notes that for patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). However, the label does not provide specific guidance on the optimal duration of use for fracture prevention, noting that the optimal duration has not been determined and that for low-risk patients, drug discontinuation after 3 to 5 years may be considered (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). This lack of definitive duration guidance may leave some patients exposed to long-term bisphosphonate therapy without clear risk-benefit assessment for ONJ. Causation-related considerations for affected patients require careful evaluation of the temporal relationship between Fosamax exposure and ONJ onset. The time to onset of symptoms varied from one day to several months after starting the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Most patients had relief of symptoms after stopping, and a subset had recurrence of symptoms when rechallenged with the same drug or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). This pattern supports a causal relationship, as symptoms improve upon drug cessation and recur upon re-exposure. However, in placebo-controlled clinical studies of Fosamax, the percentages of patients with these symptoms were similar in the Fosamax and placebo groups (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56), indicating that ONJ is a rare event that may not be captured in typical trial populations. The timeline between exposure and documented harm can range from months to years, with longer exposure increasing risk. For patients who develop ONJ, management includes discontinuation of the bisphosphonate, conservative debridement, infection control, and avoidance of further invasive dental procedures. In summary, scientific evidence establishes a plausible causal link between Fosamax and ONJ through its pharmacological suppression of bone remodeling, supported by clinical reports and mechanistic studies. The adequacy of warnings is present but limited by the lack of definitive guidance on treatment duration. Affected patients should consider the temporal relationship of their symptoms to drug exposure and consult with healthcare providers regarding risk mitigation strategies.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is Fosamax and how does it work?

Fosamax (alendronate sodium) is a bisphosphonate medication used to treat and prevent osteoporosis, increase bone mass in men with osteoporosis, treat glucocorticoid-induced osteoporosis, and treat Paget's disease of bone. It works by inhibiting bone resorption, which reduces fracture risk but also alters normal bone remodeling (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

What is osteonecrosis of the jaw (ONJ) and what are its symptoms?

Osteonecrosis of the jaw (ONJ) is a condition characterized by exposed, non-healing bone in the jaw that persists for more than eight weeks. Symptoms often include pain, swelling, infection, or delayed healing after dental procedures. It can occur spontaneously but is often associated with tooth extraction or local infection (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

What is the scientific evidence linking Fosamax to ONJ?

Scientific evidence establishes a plausible causal link through Fosamax's suppression of bone remodeling, which impairs jawbone repair. Clinical reports show that ONJ symptoms often improve after stopping Fosamax and may recur upon re-exposure, supporting causation. However, in clinical trials, ONJ rates were similar between Fosamax and placebo, indicating it is a rare event (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

What are the risk factors for developing ONJ while taking Fosamax?

Risk factors include invasive dental procedures (e.g., tooth extraction, implants), cancer diagnosis, concomitant therapies (chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders like periodontal disease, anemia, or infection. Longer duration of bisphosphonate use also increases risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

Are the warnings about ONJ on Fosamax's label adequate?

The label includes a specific section on ONJ and notes that discontinuation may reduce risk for patients needing invasive dental procedures. However, it lacks definitive guidance on optimal treatment duration, which may leave some patients exposed without clear risk-benefit assessment (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Fosamax exposure and a confirmed Osteonecrosis of the Jaw diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.